Vor Bio Posts $481.6M Cash Pile, Extends Runway Into Early 2029
VOR has more than doubled off its 52-week low of $6.5.
Summary
Vor Bio ended Q3 2026 with $481.6 million in cash and marketable securities, enough to fund operations into early 2029 — a long runway for a clinical-stage company that carries a going concern warning from its August 10-Q. Spending is climbing as the telitacicept programs scale: R&D rose to $34.5 million from $14.1 million a year ago and G&A to $23.9 million from $14.0 million. The $86.7 million net loss looks large but is mostly a warrant fair-value swing; the prior-year quarter showed an $812.7 million loss on the same accounting item. On the pipeline, UPSTREAM MG is fully enrolled with topline in 1H27, and they plan a new Phase 3 in ocular myasthenia gravis with first dosing also in 1H27. The cash position plus the September shelf registration means dilution risk remains the main overhang; topline UPSTREAM MG data in 1H27 is the next real binary.
At the time of this announcement, VOR was trading at $20.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.50 to $26.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.